Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 631 • 2014 ACR/ARHP Annual Meeting
Joint and Bone Related Pathways Discriminate Psoriatic Arthritis Lesional Skin from Psoriasis vulgaris Lesional Skin
Jennifer Belasco¹, James S. Louie², Nicholas Gulati¹, Nathan Wei³, Kristine Nograles⁴, Hiroshi Mitsui¹, Mayte Suarez-Farinas¹ and James G. Krueger¹, ¹Krueger Laboratory, The Rockefeller University, New York, NY, ²Rheumatology, UCLA School of Medicine, Los Angeles, CA, ³Arthritis & Osteoporosis Center of MD, Frederick, MD, ⁴The Rockefeller University, New York, NY
Background/Purpose: It is preferable to start therapy as early as possible in psoriatic arthritis (PsA) because of the destructive nature of the arthritis. Starting treatment…
Abstract Number: 630 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Bone Remodeling Are Elevated in Psoriatic Arthritis
Fatima Abji¹, Arane Thavaneswaran¹, Vinod Chandran^1,2 and Dafna D. Gladman^1,3, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that develops in about a third of patients with cutaneous psoriasis (PsC). The identification of biomarkers to…
Abstract Number: 625 • 2014 ACR/ARHP Annual Meeting
Fine-Mapping Major Histocompatibility Complex Associations Identified Contribution of Multiple Class I and II HLA Genes on Risk of Psoriasis and Its Clinical Subtypes
Yukinori Okada¹, Buhm Han², Lam C. Tsoi³, Philip E. Stuart⁴, Eva Ellinghaus⁵, Trilokraj Tejasvi⁶, Vinod Chandran⁷, Fawnda Pellett⁸, Remy Pollock⁹, Anne M. Bowcock¹⁰, Gerald G. Krueger¹¹, Michael Weichenthal⁵, John J. Voorhees⁶, Proton Rahman¹², Peter K. Gregersen¹³, Andre Franke¹⁴, Rajan P. Nair⁶, Gonçalo R. Abecasis¹⁵, Dafna D. Gladman⁷, James T. Elder⁶, Paul IW. de Bakker¹⁶ and Soumya Raychaudhuri¹⁷, ¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ²Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, ³Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, ⁴Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Christian-Albrechts-University of Kiel, Kiel, Germany, ⁶University of Michigan Medical School, Ann Arbor, MI, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰Imperial College, London, United Kingdom, ¹¹Dermatology, University of Utah, Salt Lake City, UT, ¹²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ¹³The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁴Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶University Medical Center, Utrecht, Netherlands, ¹⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis vulgaris (PsV) risk is strongly associated with genetic variation within the major histocompatibility complex (MHC) region, although its fine genetic architecture has not…
Abstract Number: 57 • 2014 ACR/ARHP Annual Meeting
Risk of Hospitalized Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis (PsO)/Psoriatic arthritis (PsA) often requires treatment with systemic immunosuppressive agents, some of which may increase hospitalized infection risk. Few population-based studies to date…
Abstract Number: 2099 • 2014 ACR/ARHP Annual Meeting
Serum C-X-C Motif Chemokine 10 (CXCL10) Is Elevated in Psoriasis Patients Prior to Psoriatic Arthritis Onset
Remy Pollock¹, Fatima Abji¹, Husain Shakil¹, Kun Liang², Vinod Chandran¹ and Dafna D. Gladman^1,3, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a potentially destructive disease that develops in about 30% of patients with cutaneous psoriasis. Biomarkers that can predict which psoriasis…
Abstract Number: 1915 • 2014 ACR/ARHP Annual Meeting
IL-17 Gene Transfer induces Myeloid Precursor Cells That Initiate Epidermal Hyperplasia Independently of IL-23R⁺/CD4⁺ and γδ T Cells
Erika Suzuki¹, Ritu Sarin², Emanual Maverakis¹ and Iannis E. Adamopoulos², ¹University of California at Davis, Sacramento, CA, ²Internal Medicine, University of California at Davis, Sacramento, CA
Background/Purpose: IL-17 is elevated in both the lesional skin and arthritic joints of psoriatic arthritis (PsA) patients. Although the IL-23/IL-17 axis has been linked with…
Abstract Number: 1851 • 2014 ACR/ARHP Annual Meeting
Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
Robert Kalb¹, David Fiorentino², Mark Lebwohl³, Craig Leonardi⁴, John Toole⁵, Kavitha Goyal⁶, Steve Calabro⁶, Wayne Langholff⁷ and Steve Fakharzadeh⁸, ¹SUNY at Buffalo, School of Medicine and Biological Sciences, Buffalo, NY, ²Dermatology, Stanford University, Redwood City, CA, ³Mount Sinai Medical Center, New York, NY, ⁴Central Dermatology, St. Louis, MO, ⁵University of Manitoba, Dermadvances Research, Winnipeg, MB, Canada, ⁶Janssen Services, LLC, Horsham, PA, ⁷Janssen Research and Development, LLC, Spring House, PA, ⁸Janssen Services, LLC, Spring House, PA
Background/Purpose To report the cumulative rates of serious infections in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study. Methods PSOLAR is a multicenter, longitudinal, observational…
Abstract Number: 1591 • 2014 ACR/ARHP Annual Meeting
Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis
M. Elaine Husni¹, Danielle Brennan², WH Wilson Tang³ and Stanley Hazen³, ¹Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Cardiology, CCF, Cleveland, OH
Background/Purpose Psoriatic diseases are systemic inflammatory joint and skin disorders associated with increased cardiovascular (CV) morbidity. Paraoxonase (PON) and Arylesterase (ARYL) are antioxidant enzymatic proteins…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].